Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Amyloid-beta plaques are extracellular deposits primarily composed of aggregated amyloid beta peptides (Aβ), which accumulate in the brain and are a defining neuropathological hallmark of Alzheimer's disease. They exist in different forms, with dense-core plaques being more closely associated with neurodegeneration and cognitive decline. Therapeutic strategies targeting Aβ plaques aim to reduce their formation, promote their clearance, or neutralize their toxic effects.
Target for therapies aiming to reduce Aβ production, aggregation, or promote clearance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Amyloid-beta Plaque (Aβ Plaque).